QURE · Uniqure N.V. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.56M | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $219.0K | - | $398.0K | $656.0K | $197.0K | - | $264.0K | $234.0K | $150.0K | - |
| Gross Profit | $3.34M | - | - | - | - | - | - | - | - | - |
| R&D | $29.18M | - | $34.37M | $35.38M | $36.14M | - | $30.59M | $33.66M | $40.69M | - |
| SG&A | $20.07M | - | $19.44M | $13.50M | $10.91M | - | $11.57M | $15.77M | $13.94M | - |
| Total Operating Expenses | $49.46M | - | $54.20M | $49.54M | $47.24M | - | $43.19M | $56.88M | $63.85M | - |
| D&A | $2.96M | - | - | - | $4.53M | - | - | - | $2.63M | - |
| Operating Income | ($45.72M) | - | ($51.03M) | ($43.87M) | ($39.33M) | - | ($40.23M) | ($44.01M) | ($54.23M) | - |
| Interest Expense | $14.03M | - | $16.72M | $15.59M | $16.10M | - | $16.61M | $16.16M | $16.10M | - |
| Income Tax | $488.0K | - | $8.63M | $425.0K | $496.0K | - | ($31.0K) | $948.0K | $656.0K | - |
| Net Income | ($53.53M) | - | ($44.38M) | ($56.30M) | ($43.64M) | - | ($44.38M) | ($56.30M) | ($65.62M) | - |
| EPS - Basic | ($0.85) | - | ($1.38) | ($0.69) | ($0.82) | - | ($0.91) | ($1.16) | ($1.36) | - |
| EPS - Diluted | ($0.85) | - | ($1.38) | ($0.69) | ($0.82) | - | ($0.91) | ($1.16) | ($1.36) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $139.99M | $80.24M | $597.06M | $253.78M | $217.23M | $158.93M | $251.63M | $287.88M | $243.06M | $241.36M |
| Accounts Receivable | $5.86M | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | $7.67M | $12.02M |
| Accounts Payable | $4.40M | $5.17M | $6.23M | $5.54M | $5.27M | $7.23M | $5.44M | $4.41M | $5.23M | $6.59M |
| Current Assets | $615.74M | $655.99M | $716.19M | $408.57M | $435.42M | $390.29M | $464.14M | $591.97M | $596.00M | $651.85M |
| Total Assets | $778.71M | $824.91M | $888.38M | $584.89M | $605.40M | $556.54M | $645.81M | $730.85M | $770.05M | $831.69M |
| Current Liabilities | $59.20M | $62.92M | $100.63M | $40.93M | $36.31M | $40.05M | $71.27M | $80.47M | $63.47M | $73.67M |
| Long-term Debt | $49.94M | $49.70M | $51.88M | $51.84M | $51.59M | $51.32M | $51.11M | $102.51M | $102.12M | $101.75M |
| Total Liabilities | $629.36M | $626.01M | $659.64M | $588.89M | $571.72M | $563.29M | $589.99M | $633.74M | $623.30M | $624.02M |
| Stockholders' Equity | $149.34M | $198.90M | $228.75M | ($4.00M) | $33.69M | ($6.75M) | $55.82M | $97.11M | $146.75M | $207.67M |
| Retained Earnings | ($1.38B) | ($1.33B) | ($1.29B) | ($1.21B) | ($1.17B) | ($1.13B) | ($1.06B) | ($1.01B) | ($956.03M) | ($890.41M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($38.24M) | - | - | - | ($44.10M) | - | - | - | ($60.58M) | - |
| Investing Cash Flow | $98.56M | - | - | - | $20.10M | - | - | - | $63.98M | - |
| Financing Cash Flow | $550.0K | - | - | - | $80.67M | - | - | - | - | - |
| CapEx | $140.0K | - | - | - | $126.0K | - | - | - | $2.34M | - |
| Free Cash Flow | ($38.38M) | - | - | - | ($44.23M) | - | - | - | ($62.92M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 93.9% | - | - | - | - | - | - | - | - | - |
| Operating margin | -1283.5% | - | - | - | - | - | - | - | - | - |
| EBITDA margin | -1200.6% | - | - | - | - | - | - | - | - | - |
| Net margin | -1502.9% | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | -1077.6% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.72 | - | - | - | 1.01 | - | - | - | 0.96 | - |
| R&D / Revenue | 819.1% | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 563.4% | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.9% | - | -5.0% | -9.6% | -7.2% | - | -6.9% | -7.7% | -8.5% | - |
| Return on equity | -35.8% | - | -19.4% | 1406.4% | -129.5% | - | -79.5% | -58.0% | -44.7% | - |
| Return on invested capital | -18.1% | - | -14.4% | -72.4% | -36.4% | - | -29.7% | -17.4% | -17.2% | - |
| Liquidity | ||||||||||
| Current ratio | 10.40 | 10.43 | 7.12 | 9.98 | 11.99 | 9.74 | 6.51 | 7.36 | 9.39 | 8.85 |
| Quick ratio | 10.40 | 10.43 | 7.12 | 9.98 | 11.99 | 9.74 | 6.51 | 7.36 | 9.27 | 8.68 |
| Cash ratio | 2.36 | 1.28 | 5.93 | 6.20 | 5.98 | 3.97 | 3.53 | 3.58 | 3.83 | 3.28 |
| Leverage | ||||||||||
| Debt / Equity | 0.33 | 0.25 | 0.23 | -12.95 | 1.53 | -7.60 | 0.92 | 1.06 | 0.70 | 0.49 |
| Debt / Assets | 0.06 | 0.06 | 0.06 | 0.09 | 0.09 | 0.09 | 0.08 | 0.14 | 0.13 | 0.12 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -3.3x | - | -3.1x | -2.8x | -2.4x | - | -2.4x | -2.7x | -3.4x | - |
| Equity multiplier | 5.21 | 4.15 | 3.88 | -146.11 | 17.97 | -82.43 | 11.57 | 7.53 | 5.25 | 4.00 |
| Liabilities / Assets | 0.81 | 0.76 | 0.74 | 1.01 | 0.94 | 1.01 | 0.91 | 0.87 | 0.81 | 0.75 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | 0.02 | - |
| Days sales outstanding | 601d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | 18669d | - |
| Days payable outstanding | 7332d | - | 5712d | 3083d | 9761d | - | 7523d | 6874d | 12729d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.9x | - | 14.9x | - | 16.7x | - | 4.3x | 2.2x | 1.7x | - |
| P / S | 288.0x | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -16.2% | - | -26.9% | 0.3% | 27.5% | - | 50.9% | 32.4% | 26.9% | - |
| Net income growth (YoY) | -22.7% | - | 0.0% | 0.0% | 33.5% | - | 50.5% | 17.8% | 15.0% | - |
| EPS growth (YoY) | -3.7% | - | -51.6% | 40.5% | 39.7% | - | 51.6% | 19.4% | 16.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 13.2% | - | - | - | 29.7% | - | - | - | 22.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 343.3% | - | 309.8% | - | -77.0% | - | -79.2% | -72.5% | -64.4% | -56.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing uniQure N.V. against the 5 most active filers in the same SIC group.